US2013150312A1PendingUtilityA1

Topical antiviral formulations

50
Individually held — no corporate assignee on recordPriority: Oct 3, 2008Filed: Jun 14, 2012Published: Jun 13, 2013
Est. expiryOct 3, 2028(~2.2 yrs left)· nominal 20-yr term from priority
Inventors:Darby C. BrownKristen Brown
A61K 31/522A61K 9/0014A61K 31/7004A61P 31/12
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The disclosure provides antiviral pharmaceutical compositions comprising one or more antiviral compounds and 2-deoxy-D-glucose in the form of lip-balms, creams and ointments. A specific embodiment discloses a lip-balm composition comprising acyclovir and 2-deoxy-D-glucose.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A pharmaceutical composition comprising a therapeutically effective amount of an antiviral compound selected from one or more of the group consisting of acyclovir, vidarabine, azidothymidine, ganciclovir, famciclovir, penciclovir, brivudine, cidofovir, trifluridine, foscarnet, and a pharmaceutically acceptable salt or hydrate thereof; and
 a therapeutically effective amount of 2-deoxy-D-glucose.   
     
     
         2 . The composition of  claim 1 , wherein the antiviral compound is selected from the group consisting of acyclovir, famciclovir, penciclovir, and foscarnet. 
     
     
         3 . The composition of  claim 2  wherein the antiviral compound is acyclovir. 
     
     
         4 . The composition of  claim 1  in a form selected from a lip-balm, stick, cream or ointment. 
     
     
         5 . The composition of  claim 4  in a lip-balm form. 
     
     
         6 . The composition of  claim 5 , further comprising one or more polyethylene glycols. 
     
     
         7 . The composition of  claim 6 , further comprising one or more sweeteners or flavorings. 
     
     
         8 . The composition of  claim 7  wherein the sweetener is stevioside. 
     
     
         9 . The composition of  claim 7  wherein the flavoring is spearmint oil. 
     
     
         10 . The composition of  claim 3  wherein the composition comprises from about 3 wt % to about 7 wt % of acyclovir and from about 0.1 wt % to about 5 wt % of 2-deoxy-D-glucose. 
     
     
         11 . The composition of  claim 10  wherein the composition comprises about 5 wt % of acyclovir and about 0.2 wt % of 2-deoxy-D-glucose. 
     
     
         12 . A method of treating a herpes viral infection of a patient in need thereof comprising administering a pharmaceutical composition comprising a therapeutically effective amount of an antiviral compound selected from the group consisting of acyclovir, vidarabine, azidothymidine, ganciclovir, famciclovir, penciclovir, brivudine, cidofovir, trifluridine, foscarnet, and a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of 2-deoxy-D-glucose. 
     
     
         13 . The method of  claim 12 , wherein the antiviral compound is acyclovir. 
     
     
         14 . The method of  claim 12 , wherein the composition is in a form selected from a lip-balm, stick, cream or ointment. 
     
     
         15 . The method of  claim 14 , wherein the composition is in a lip-balm form. 
     
     
         16 . The method of  claim 13 , wherein the composition comprises from about 3 wt % to about 7 wt % of acyclovir and from about 0.1 wt % to about 5 wt % of 2-deoxy-D-glucose. 
     
     
         17 . The method of  claim 16 , wherein the topical comprises about 5 wt % of acyclovir and about 0.2 wt % of 2-deoxy-D-glucose. 
     
     
         18 . The method of  claim 12 , wherein the treatment is for latent infection of herpes simplex type 1 infection. 
     
     
         19 . The method of  claim 12 , wherein the treatment is for latent infection of herpes simplex type 2 infection. 
     
     
         20 . The method of  claim 12 , wherein the infection is an orofacial herpes infection. 
     
     
         21 . A method of reducing the duration of a herpes viral infection outbreak in a mammal in need thereof comprising administering a pharmaceutical composition comprising a therapeutically effective amount of an antiviral compound selected from the group consisting of acyclovir, vidarabine, azidothymidine, ganciclovir, famciclovir, penciclovir, brivudine, cidofovir, trifluridine, foscarnet, and a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of 2-deoxy-D-glucose. 
     
     
         22 . The method of  claim 21 , wherein the antiviral compound is selected from the group consisting of acyclovir, famciclovir, penciclovir, and foscarnet. 
     
     
         23 . The method of  claim 21 , wherein the antiviral compound is acyclovir. 
     
     
         24 . The method of  claim 21  wherein the treatment is for latent infection of herpes simplex type 1 infection. 
     
     
         25 . The method of  claim 21 , wherein the treatment is for latent infection of herpes simplex type 2 infection. 
     
     
         26 . The method of  claim 21 , wherein the infection is an orofacial herpes infection.

Join the waitlist — get patent alerts

Track US2013150312A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.